These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 16229996)

  • 21. Advances in mosquito allergy.
    Peng Z; Simons FE
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):350-4. PubMed ID: 17620829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant allergens: what does the future hold?
    Valenta R; Niespodziana K; Focke-Tejkl M; Marth K; Huber H; Neubauer A; Niederberger V
    J Allergy Clin Immunol; 2011 Apr; 127(4):860-4. PubMed ID: 21458656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Allergic desensitization: review of controlled clinical trials].
    Pécoud A
    Schweiz Med Wochenschr; 1985 Nov; 115(46):1651-3. PubMed ID: 3909392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient-tailored recombinant allergen products--mission impossible?
    Cromwell O; Matricardi PM; Fiebig H
    Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():210-7; discussion 217-8. PubMed ID: 20799463
    [No Abstract]   [Full Text] [Related]  

  • 25. Allergen-related approaches to immunotherapy.
    Rolland JM; Gardner LM; O'Hehir RE
    Pharmacol Ther; 2009 Mar; 121(3):273-84. PubMed ID: 19111571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA-based vaccines for allergic disease.
    Spiegelberg HL; Takabayashi K; Beck L; Raz E
    Expert Rev Vaccines; 2002 Aug; 1(2):169-77. PubMed ID: 12901556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biotechnology-based allergy diagnosis and vaccination.
    Bhalla PL; Singh MB
    Trends Biotechnol; 2008 Mar; 26(3):153-61. PubMed ID: 18222557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives.
    Linhart B; Valenta R
    Vaccine; 2012 Jun; 30(29):4328-35. PubMed ID: 22100888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specific immunotherapy, one century later.
    Passalacqua G; Bush RK
    Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):551-3. PubMed ID: 21971328
    [No Abstract]   [Full Text] [Related]  

  • 30. Allergy vaccines: dreams and reality.
    Crameri R
    Expert Rev Vaccines; 2007 Dec; 6(6):991-9. PubMed ID: 18377361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant mite allergens: validation strategies and clinical trials.
    Chapman MD
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2003; (94):205-10; discussion 210-2. PubMed ID: 15119041
    [No Abstract]   [Full Text] [Related]  

  • 32. Novel ways for immune intervention in immunotherapy: mucosal allergy vaccines.
    Mascarell L; Van Overtvelt L; Moingeon P
    Immunol Allergy Clin North Am; 2006 May; 26(2):283-306, vii-viii. PubMed ID: 16701145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A recombinant allergen chimer as novel mucosal vaccine candidate for prevention of multi-sensitivities.
    Wild C; Wallner M; Hufnagl K; Fuchs H; Hoffmann-Sommergruber K; Breiteneder H; Scheiner O; Ferreira F; Wiedermann U
    Allergy; 2007 Jan; 62(1):33-41. PubMed ID: 17156339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.
    Pauli G; Larsen TH; Rak S; Horak F; Pastorello E; Valenta R; Purohit A; Arvidsson M; Kavina A; Schroeder JW; Mothes N; Spitzauer S; Montagut A; Galvain S; Melac M; André C; Poulsen LK; Malling HJ
    J Allergy Clin Immunol; 2008 Nov; 122(5):951-60. PubMed ID: 19000581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel immunotherapy vaccine development.
    Jutel M; Akdis CA
    Curr Opin Allergy Clin Immunol; 2014 Dec; 14(6):557-63. PubMed ID: 25304230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical trials with recombinant allergens: research studies?
    Pauli G
    Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():257-64; discussion 264-5. PubMed ID: 20799469
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical evaluation of genetically engineered hypoallergenic rBet v 1 derivatives.
    Pauli G; Purohit A; Oster JP; de Blay F; Vrtala S; Niederberger V; Kraft D; Valenta R
    Int Arch Allergy Immunol; 1999; 118(2-4):216-7. PubMed ID: 10224385
    [No Abstract]   [Full Text] [Related]  

  • 38. Design, engineering and in vitro evaluation of MHC class-II targeting allergy vaccines.
    Crameri R; Flückiger S; Daigle I; Kündig T; Rhyner C
    Allergy; 2007 Feb; 62(2):197-206. PubMed ID: 17298430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA vaccines for allergy treatment.
    Hartl A; Weiss R; Hochreiter R; Scheiblhofer S; Thalhamer J
    Methods; 2004 Mar; 32(3):328-39. PubMed ID: 14962768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic engineering of allergens: future therapeutic products.
    Ferreira F; Wallner M; Breiteneder H; Hartl A; Thalhamer J; Ebner C
    Int Arch Allergy Immunol; 2002 Jul; 128(3):171-8. PubMed ID: 12119498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.